Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.34 |
| ▸ | SYK | P43405 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA7 | P43166 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 3/20 | 0.32 |
| ▸ | AHR | P35869 | 1/20 | 0.32 |
| ▸ | FOS | P01100 | 1/20 | 0.32 |
| ▸ | JUN | P05412 | 1/20 | 0.32 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.32 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.32 |
| ▸ | RELA | Q04206 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20980332 | 0.84 | MEN1 (0.36) | LMNAKDM4EMEN1KMT2AHTT | |
| SCHEMBL13344758 | 0.84 | MEN1 (0.39) | LMNAKDM4EMEN1KMT2AHTT | |
| SCHEMBL14609722 | 0.82 | LMNA (0.40) | LMNAKDM4EMEN1KMT2AHTT | |
| SCHEMBL15785397 | 0.82 | LMNA (0.40) | LMNAKDM4EMEN1KMT2AHTT | |
| SCHEMBL5067063 | 0.81 | MEN1 (0.34) | LMNAKDM4EMEN1KMT2AALDH1A1 | |
| SCHEMBL1521840 | 0.81 | ALDH1A1 (0.40) | LMNAKDM4EMEN1KMT2AHTT | |
| SCHEMBL6247194 | 0.80 | LRRK2 (0.31) | — | |
| SCHEMBL22860110 | 0.80 | GLP1R (0.36) | LMNAMEN1KMT2AHTTALDH1A1 | |
| SCHEMBL10811677 | 0.79 | AHR (0.43) | LMNAKDM4EMEN1KMT2AALDH1A1 | |
| SCHEMBL23142064 | 0.79 | MEN1 (0.33) | KDM4EMEN1KMT2AALDH1A1NTRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 331 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12624032-B2 | Pyrido[2,3-d]pyrimidin-7-ones and related compounds as inhibitors of protein kinases | UNIVERSITY OF HOUSTON SYSTEM (US) | 2026-05-12 | — | — | US | disclosed |
| US-12590098-B2 | Pyrimido pyrimidinone compound and pharmaceutical composition comprising the same | AXCESO BIOPHARMA CO., LTD. (KR) | 2026-03-31 | — | — | US | disclosed |
| US-20260070913-A1 | 7-AMINO-3,4-DIHYDROPYRIMIDOPYRIMIDIN-2-ONE DERIVATIVE HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASES AND THERAPEUTIC PHARMACEUTICAL COMPOSITION COMPRISING SAME | KOREA INST SCI & TECH (KR) | 2026-03-12 | — | — | US | disclosed |
| EP-4215533-B1 | PYRIMIDOPYRIMIDINONE COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | AXCESO BIOPHARMA CO LTD (KR) | 2026-02-11 | — | — | EP | disclosed |
| US-20260021095-A1 | BIFUNCTIONAL COMPOUNDS CONTAINING PYRIDO[2,3-d]PYRIMIDIN-7(8H)-ONE DERIVATIVES FOR DEGRADING CYCLIN-DEPENDENT KINASE 2 VIA UBIQUITIN PROTEASOME PATHWAY | NIKANG THERAPEUTICS INC (US) | 2026-01-22 | — | — | US | disclosed |
| US-12516055-B2 | Protein kinase inhibitors and uses thereof for the treatment of diseases and conditions | TRUSTEES OF TUFTS COLLEGE (US) | 2026-01-06 | — | — | US | disclosed |
| US-20250221998-A1 | DISCOVERY OF COVALENT EGFR INHIBITOR THROUGH CYSTEINE 775 | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2025-07-10 | — | — | US | disclosed |
| WO-2025137391-A1 | BIFUNCTIONAL COMPOUNDS CONTAINING PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONE DERIVATIVES FOR DEGRADING CYCLIN-DEPENDENT KINASE 4 VIA UBIQUITIN PROTEASOME PATHWAY | NIKANG THERAPEUTICS, INC. (US) | 2025-06-26 | — | — | WO | disclosed |
| WO-2025137385-A1 | BIFUNCTIONAL COMPOUNDS CONTAINING PYRIDO[2,3-D]P¥RIMIDIN-7(8H)-ONE DERIVATIVES FOR DEGRADING CYCLIN-DEPENDENT KINASE 2 AND CYCLIN- DEPENDENT KINASE 4 VIA UBIQUITIN PROTEASOME PATHWAY | NIKANG THERAPEUTICS, INC. (US) | 2025-06-26 | — | — | WO | disclosed |
| EP-4543889-A1 | BIFUNCTIONAL COMPOUNDS CONTAINING PYRIDO[2,3-DJPYRIMIDIN-7(8H)-ONE DERIVATIVES FOR DEGRADING CYCLIN-DEPENDENT KINASE 2 VIA UBIQUITIN PROTEASOME PATHWAY | Nikang Therapeutics, Inc. (US) | 2025-04-30 | — | — | EP | disclosed |
| WO-2001029042-A1 | HETEROALKYLAMINO-SUBSTITUTED BICYCLIC NITROGEN HETEROCYCLES AS INHIBITORS OF P38 PROTEIN KINASE | F. HOFFMANN-LA ROCHE AG (CH) | 2001-04-26 | — | — | WO | disclosed |
| US-6150373-A | AMINO-SUBSTITUTED DIHYDROPYRIMIDO(4,5-D)PYRIMIDINONE DERIVATIVES; INHIBITORS OF THE T-CELL TYROSINE KINASE P56LCK; IMMUNOSUPPRESSANTS; ANTIINFLAMMATORY/-CARCINOGENIC AGENTS; BRONCHOPULMONARY, DERMATOLOGICAL AND CARDIOVASCULAR DISORDERS | HOFFMANN-LA ROCHE INC. (US) | 2000-11-21 | — | — | US | disclosed |
| WO-2000024744-A1 | BICYCLIC NITROGEN HETEROCYCLES | F. HOFFMANN-LA ROCHE AG (CH) | 2000-05-04 | — | — | WO | disclosed |
| EP-0964864-A2 | PYRIDO 2,3-D] PYRIMIDINES AND 4-AMINOPYRIMIDINES AS INHIBITORS OF CELLULAR PROLIFERATION | WARNER-LAMBERT COMPANY (US) | 1999-12-22 | — | — | EP | disclosed |
| US-5945422-A | ANTICANCER AGENTS; ATHEROSCLEROSIS; RESTENOSIS; PSORIASIS | WARNER-LAMBERT COMPANY (US) | 1999-08-31 | — | — | US | disclosed |
| WO-1998033798-A2 | PYRIDO[2,3-D]PYRIMIDINES AND 4-AMINO-PYRIMIDINES AS INHIBITORS OF CELL PROLIFERATION | WARNER LAMBERT COMPANY (US) | 1998-08-06 | — | — | WO | disclosed |
| US-5733914-A | Pyrido 2, 3-d!pyrimidines for inhibiting protein tyrosine kinase mediated cellular proliferation | WARNER-LAMBERT COMPANY (US) | 1998-03-31 | — | — | US | disclosed |
| EP-0823908-A1 | PYRIDO 2,3-d]PYRIMIDINES FOR INHIBITING PROTEIN TYROSINE KINASE MEDIATED CELLULAR PROLIFERATION | WARNER-LAMBERT COMPANY (US) | 1998-02-18 | — | — | EP | disclosed |
| US-5620981-A | ANTICARCINOGENIC AGENTS, ATHEROSCLEROSIS, RESTENOSIS, PSORIASIS | WARNER-LAMBERT COMPANY (US) | 1997-04-15 | — | — | US | disclosed |
| WO-1996034867-A1 | PYRIDO[2,3-d]PYRIMIDINES FOR INHIBITING PROTEIN TYROSINE KINASE MEDIATED CELLULAR PROLIFERATION | WARNER-LAMBERT COMPANY (US) | 1996-11-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260021095-A1 | BIFUNCTIONAL COMPOUNDS CONTAINING PYRIDO[2,3-d]PYRIMIDIN-7(8H)-ONE DERIVATIVES FOR DEGRADING CYCLIN-DEPENDENT KINASE 2 VIA UBIQUITIN PROTEASOME PATHWAY | PSMB2, PSMB7, MDM2 | LMNA 1761/4885KDM4E 1441/4885MEN1 4386/4885 |
| US-20260070913-A1 | 7-AMINO-3,4-DIHYDROPYRIMIDOPYRIMIDIN-2-ONE DERIVATIVE HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASES AND THERAPEUTIC PHARMACEUTICAL COMPOSITION COMPRISING SAME | CSNK1A1, CKS1B, HGFAC | LMNA 1222/4885KDM4E 3599/4885MEN1 3076/4885 |
| US-12624032-B2 | Pyrido[2,3-d]pyrimidin-7-ones and related compounds as inhibitors of protein kinases | RIPK2, RIPK1, RIPK4 | LMNA 790/4885KDM4E 851/4885MEN1 2758/4885 |
| US-12590098-B2 | Pyrimido pyrimidinone compound and pharmaceutical composition comprising the same | PDCD1, CD274, PDCD1LG2 | LMNA 2148/4885KDM4E 334/4885MEN1 715/4885 |
| US-20250221998-A1 | DISCOVERY OF COVALENT EGFR INHIBITOR THROUGH CYSTEINE 775 | EGFR, ERBB2, ERBB3 | LMNA 4577/4885KDM4E 2321/4885MEN1 4677/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.